FR2565490B1 - Solide sec hydrosoluble renfermant une substance proteinique bioactive - Google Patents

Solide sec hydrosoluble renfermant une substance proteinique bioactive

Info

Publication number
FR2565490B1
FR2565490B1 FR8507935A FR8507935A FR2565490B1 FR 2565490 B1 FR2565490 B1 FR 2565490B1 FR 8507935 A FR8507935 A FR 8507935A FR 8507935 A FR8507935 A FR 8507935A FR 2565490 B1 FR2565490 B1 FR 2565490B1
Authority
FR
France
Prior art keywords
water soluble
soluble solid
solid containing
dry water
bioactive protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8507935A
Other languages
English (en)
Other versions
FR2565490A1 (fr
Inventor
Shunsaku Koyama
Toshio Miyake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hayashibara Seibutsu Kagaku Kenkyujo KK
Original Assignee
Hayashibara Seibutsu Kagaku Kenkyujo KK
Hayashibara Biochemical Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hayashibara Seibutsu Kagaku Kenkyujo KK, Hayashibara Biochemical Laboratories Co Ltd filed Critical Hayashibara Seibutsu Kagaku Kenkyujo KK
Publication of FR2565490A1 publication Critical patent/FR2565490A1/fr
Application granted granted Critical
Publication of FR2565490B1 publication Critical patent/FR2565490B1/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR8507935A 1984-06-06 1985-05-28 Solide sec hydrosoluble renfermant une substance proteinique bioactive Expired FR2565490B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59116158A JPS60258125A (ja) 1984-06-06 1984-06-06 蛋白性生理活性物質を含有する水溶性乾燥物

Publications (2)

Publication Number Publication Date
FR2565490A1 FR2565490A1 (fr) 1985-12-13
FR2565490B1 true FR2565490B1 (fr) 1987-12-11

Family

ID=14680207

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8507935A Expired FR2565490B1 (fr) 1984-06-06 1985-05-28 Solide sec hydrosoluble renfermant une substance proteinique bioactive

Country Status (5)

Country Link
US (1) US4824938A (fr)
JP (1) JPS60258125A (fr)
DE (1) DE3520228C2 (fr)
FR (1) FR2565490B1 (fr)
GB (1) GB2160528B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0193917A3 (fr) * 1985-03-06 1987-09-23 American Cyanamid Company Compositions dispersibles et solubles dans l'eau de polymères pour administration parentérale
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
JP2577743B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
NZ235556A (en) * 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
NZ226557A (en) * 1987-10-15 1990-07-26 Syntex Inc Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
GB8826429D0 (en) * 1988-11-11 1988-12-14 Univ Leeds Ind Service Ltd Enzyme stabilisation systems
USRE39497E1 (en) * 1989-02-16 2007-02-27 Nektar Therapeutics Storage of materials
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
US5468622A (en) * 1990-04-03 1995-11-21 Immunomatrix, Inc. Salt stabilization of antibody-enzyme conjugates heat-dried into paper
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5200399A (en) * 1990-09-14 1993-04-06 Boyce Thompson Institute For Plant Research, Inc. Method of protecting biological materials from destructive reactions in the dry state
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
NZ257212A (en) * 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
US7448375B2 (en) * 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5424301A (en) * 1993-02-01 1995-06-13 Warner-Lambert Company Starch stabilized o-substituted tetrahydropyridine oxime cholinergic agents
US5656597A (en) * 1993-04-28 1997-08-12 Akzo Nobel N.V. Lyospheres comprising gonadotropin
PT748213E (pt) * 1994-03-07 2004-08-31 Nektar Therapeutics Metodos e composicoes para administracao pulmonar de insulina
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
NZ285664A (en) * 1994-05-18 1998-07-28 Inhale Therapeutic Syst Dry powder interferon composition adapted for pulmonary delivery
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6274369B1 (en) * 1996-02-02 2001-08-14 Invitrogen Corporation Method capable of increasing competency of bacterial cell transformation
WO1997036613A1 (fr) 1996-03-29 1997-10-09 Life Technologies, Inc. Procede pour augmenter la viabilite et l'efficacite de transformation de bacteries pendant leur conservation a des temperatures basses
WO1998051328A1 (fr) * 1997-05-09 1998-11-19 Feronpatent Limited Stabilisation d'interferons dans une solution aqueuse en vue de la fabrication de pastilles que l'on administre par voie sublinguale
ES2241120T3 (es) 1997-02-12 2005-10-16 Invitrogen Corporation Metodos para liofilizar celulas competentes.
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
AU740735B2 (en) * 1997-08-01 2001-11-15 Toray Industries, Inc. Method for stabilizing useful proteins and useful protein compositions
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
EP0913177A1 (fr) 1997-11-03 1999-05-06 Roche Diagnostics GmbH Procédé pour produire des produits amorphe, sec comprenant de la matière biologique active par séchage convectif, spécialement söchage par pulvérisation
WO2001058472A2 (fr) * 2000-02-08 2001-08-16 Allergan, Inc. Compositions pharmaceutiques a base de toxine botulique
WO2001085136A2 (fr) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Poudres a base de phospholipides permettant de distribuer un medicament
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
AU2001280934A1 (en) * 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
JP2002340896A (ja) * 2001-05-22 2002-11-27 Sekisui Chem Co Ltd 免疫測定試薬
US20030091971A1 (en) * 2001-09-14 2003-05-15 Invitrogen Corporation Composition for stabilizing biological materials
EP1458360B1 (fr) 2001-12-19 2011-05-11 Novartis AG Administration pulmonaire d'aminoglycosides
JP2008501639A (ja) * 2004-04-23 2008-01-24 ノベシン リミテッド タンパク質を安定化、保護及び可溶化させるための方法及びキット
AU2005235800B2 (en) * 2004-04-23 2011-08-04 Expedeon Limited Methods and kits for stabilising, protecting and solubilising proteins
GB0416861D0 (en) * 2004-07-29 2004-09-01 Quadrant Drug Delivery Ltd Composition
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
WO2012095746A2 (fr) 2011-01-11 2012-07-19 Capsugel Belgium Nv Nouvelles gélules dures
US20130089638A1 (en) * 2011-10-11 2013-04-11 Mead Johnson Nutrition Company Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes
WO2018189587A1 (fr) 2017-04-14 2018-10-18 Capsugel Belgium Nv Procédé de fabrication de pullulane
WO2018189584A1 (fr) 2017-04-14 2018-10-18 Capsugel Belgium Nv Capsules de pullulane

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784390A (en) * 1971-07-23 1974-01-08 Hayashibara Biochem Lab Shaped bodies of pullulan and their use
US3871892A (en) * 1972-12-18 1975-03-18 Hayashibara Biochem Lab Shaped bodies of pullulan esters and their use
CA1093991A (fr) * 1977-02-17 1981-01-20 Hideo Hirohara Traduction non-disponible
GB2001955A (en) * 1977-08-03 1979-02-14 Hoffmann La Roche 1-Methyl-isoguanine
SU943280A1 (ru) * 1978-05-29 1982-07-15 Институт биоорганической химии им.М.М.Шемякина Способ консервации иммобилизованных ферментов
JPS5639022A (en) * 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
JPS5823847B2 (ja) * 1981-02-06 1983-05-18 株式会社 林原生物化学研究所 抗ヒト蛋白質抗体の製造方法
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
JPS5892691A (ja) * 1981-11-28 1983-06-02 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの安定化法
DE3360633D1 (en) * 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
JPS6059000A (ja) * 1983-09-09 1985-04-05 Kyowa Hakko Kogyo Co Ltd インタ−フェロンの安定化方法

Also Published As

Publication number Publication date
GB2160528B (en) 1988-03-09
FR2565490A1 (fr) 1985-12-13
JPS60258125A (ja) 1985-12-20
DE3520228A1 (de) 1985-12-12
DE3520228C2 (de) 1994-02-24
GB2160528A (en) 1985-12-24
GB8513502D0 (en) 1985-07-03
US4824938A (en) 1989-04-25
JPH0533208B2 (fr) 1993-05-19

Similar Documents

Publication Publication Date Title
FR2565490B1 (fr) Solide sec hydrosoluble renfermant une substance proteinique bioactive
BE887498A (fr) Pompe de distribution etanche
BR8401507A (pt) Composicao aquosa estabilizada
IT1222104B (it) Composizione farmaceutica idrosolubile contenente n acetilsisteina
BR8506336A (pt) Emulsao aquosa
BR8603908A (pt) Composicao detergente aquosa
IT1222103B (it) Composizione farmaceutica idrosolubile contenente n acetilcisteina
BR8405022A (pt) Composicao aquosa contendo enzima
DK289485D0 (da) Padleaare
TR23842A (tr) Sabun sehriyeleri iceren deterjan bilesimi
JPS55157518A (en) Stable protein water solution
FR2566260B1 (fr) Lave-bottes
FR2539237B1 (fr) Composition de developpateur sec
KR850009841U (ko) 수상 스케이트
KR860003524U (ko) 물놀이용 소형 보우트
DK298788D0 (da) Vandreservoir
KR850009217U (ko) 건어물 세절기
IT8404751V0 (it) Saponetta calleggiante
KR840006647U (ko) 물 신 발
KR860007728U (ko) 수상 보우트
IT8444206A0 (it) Tavola - ruspa trascinata
BR8406358A (pt) Sapata flutuante
KR890000370U (ko) 수상 스키이
KR840001948U (ko) 수상스키
DK447984D0 (da) Tynd brugsvandsbeholder

Legal Events

Date Code Title Description
ST Notification of lapse